Skip to main content

Top Financial Stories 2016

Image result for teachers union

I generally ask myself at this time of year what were the biggest stories of the past twelve months in business/financial news. 

Of course, I choose the ones I do largely because they illustrate an important theme, and in the list below I'll spell out and boldface the theme. Yet the theme itself isn't the story.

January:  Collective bargaining. The U.S. Supreme Court hears arguments Jan. 11th about public sector unions, mandatory fees, and the economics of the free-rider problem. In the spring, after Scalia's death, it splits 4-4 on the subject.

February: Economics of crude oil. Iran takes a stand-offish posture toward the efforts of other oil-producing nations to cut production, wants to get itself back to pre-sanctions levels.

March: Smartphones and privacy. The face-off on iPhone encryption and the demands of the FBI go before the U.S. Congress as this month begins.  Later in the month, FBI backs away, says it may have found another way.

April. Rise of Social Media. Twitter wins a bidding war for the right to stream regular season NFL games. This is illustrative of the way social media are taking over general entertainment functions, esp. in the US.

May. Commodities. After a long downturn,  basic commodities seemed to be on an upswing by May, indicated for example by Rio Tinto's $5.3 billion expansion of a copper mine in Oyu Tolgoi, in Mongolia. And by agricultural pricing.

June. European Union. Britain votes to leave, 52/48, in a referendum with enormous implications for the whole continent and beyond.

July.  Africa. Protesters in Zimbabwe demand that Robert Mugabe step down, due to deepening economic dysfunction. Some of his staunchest supporters, the war veterans, desert him.

August. Economics of health care. The degree to which the unfolding of Obamacare has not gone as planned, or advertised, becomes conspicuous, and makes a rather late but potent appearance in the Presidential campaign. In November, Trump will become President elect, with a mandate to "repeal and replace," whatever exactly that means.

September. Latin America. The People's Republic of China cuts off new loans to Venezuela, worsening the latter country's economic crisis.

October.  Market structure issues. A London-based trader, Navinder Singh Sarao, loses in his efforts to avoid extradition to the US. Sarao is blamed by many for the 2010 Wall Street "flash crash."

November. Marijuana. Several states in the US vote on two distinct tiers of proposals to legalize (at the state level) the MJ industry. Most of these proposals for liberalization are approved.

December. Automation. Uber removes its self-driving cars from the streets of San Francisco one month after launching the program there, vowing to reconsider how it can comply with California regulations. The incident reflects the way in which automation is poised to wreak havoc on various legal and social structures, and the sometimes-successful pushback by those structures.

Comments

  1. This comment has been removed by a blog administrator.

    ReplyDelete
  2. Vaporfi is the #1 electronic cigarettes supplier on the market.

    ReplyDelete

Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…